Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company's discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and...
Panacos Pharmaceuticals reported revenue of $180,000 for fiscal year 2007, down 36.6% from fiscal year 2006, and net income of -$37.46 million. In Q3 2008 (the quarter ended September 30, 2008) revenue was $24,000, down 20.0% from a year before. Its market capitalization was $321,841 as of December 3, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2007; market data as of December 3, 2025.
No profile data available.